Transplanting hematopoietic stem cells to treat cancers and other conditions carries with it the risk of developing cardio-cerebrovascular diseases (CCVD)--disorders affecting the blood vessels of the heart and brain. Although research on post-transplant CCVD is extensive, there is paucity of knowledge on the effects of pre-transplant CCVD on transplant outcomes. Now researchers in China suggest pre-transplant CCVD indirectly affects patient mortality and survival following transplant through their strong association with post-transplant CCVD.
During the height of the pandemic, some hospitals were overwhelmed with patients seeking treatment for COVID-19. This situation could happen again during future outbreaks, especially with SARS-CoV-2 variants of concern on the rise. Now, researchers reporting in ACS' Analytical Chemistry have developed a blood test to predict which people infected with COVID-19 are most likely to experience serious symptoms, which could help health care workers prioritize patients for hospitalization and intensive care.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types.
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University.
A scientific review has found evidence that a disruption in blood clotting and the first line immune system could be contributing factors in the development of psychosis.
Penn State College of Engineering researchers set out to develop technology capable of localizing and imaging blood clots in deep veins. Turns out their work may not only identify blood clots, but it may also be able to treat them.
Adequate blood flow supplies the brain with oxygen and nutrients, but the oxygenation tends to fluctuate in a distinct, consistent manner. The root of this varied activity, though, is poorly understood.
An international grassroots-funded multicenter clinical trial found that giving a full dose of heparin early to moderately ill hospitalized COVID-19 patients reduced the odds of all-cause death by 78 percent.
Scientists from the MPI-IE reveal that during hematopoietic regeneration, RNA expressed from a part of the genome considered "junk DNA" is used by hematopoietic stem cells to get activated and proliferate. The study published in the scientific journal Nature Cell Biology shows that these so-called transposable elements make RNA after chemotherapy and activate an immune receptor which induces inflammatory signals enhancing hematopoietic stem cell cycling and thus participating in the regeneration of the hematopoietic system.
For the first time, Princess Margaret researchers have mapped out where and how leukemia begins and develops in infants with Down syndrome in preclinical models, paving the way to potentially prevent this cancer in the future.